Your browser doesn't support javascript.
loading
Defining factors that influence vaccine-induced, cross-variant neutralizing antibodies for SARS-CoV-2 in Asians
Yue Gu; Bhuvaneshwari D/O Shunmuganathan; Xinlei Qian; Rashi Gupta; Rebecca S.W. Tan; Mary Kozma; Kiren Purushotorman; Tanusya M. Murali; Nikki Y.J. Tan; Peter R. Preiser; Julien Lescar; Haziq Nasir; Jyoti Somani; Paul A. Tambyah; - SCOPE Cohort Study Group; Kenneth G.C. Smith; Laurent Renia; Lisa F.P. Ng; David C. Lye; Barnaby E. Young; Paul A. MacAry.
Afiliación
  • Yue Gu; National University of Singapore
  • Bhuvaneshwari D/O Shunmuganathan; National University of Singapore
  • Xinlei Qian; National University of Singapore
  • Rashi Gupta; National University of Singapore
  • Rebecca S.W. Tan; National University of Singapore
  • Mary Kozma; National University of Singapore
  • Kiren Purushotorman; National University of Singapore
  • Tanusya M. Murali; National University of Singapore
  • Nikki Y.J. Tan; National University of Singapore
  • Peter R. Preiser; Nanyang Technological University
  • Julien Lescar; Nanyang Technological University
  • Haziq Nasir; National University Hospital
  • Jyoti Somani; National University Hospital
  • Paul A. Tambyah; National University Hospital
  • - SCOPE Cohort Study Group; -
  • Kenneth G.C. Smith; University of Cambridge
  • Laurent Renia; Agency for Science, Technology and Research (A*STAR), Singapore
  • Lisa F.P. Ng; Agency for Science, Technology and Research (A*STAR), Singapore
  • David C. Lye; National Centre of Infectious Diseases
  • Barnaby E. Young; National Centre for Infectious Diseases
  • Paul A. MacAry; National University of Singapore
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-22271809
ABSTRACT
The scale and duration of neutralizing antibody responses targeting SARS-CoV-2 viral variants represents a critically important serological parameter that predicts protective immunity for COVID-19. In this study, we present longitudinal data illustrating the impact of age, sex and comorbidities on the kinetics and strength of vaccine-induced neutralizing antibody responses for key variants in an Asian volunteer cohort. We demonstrate a reduction in neutralizing antibody titres across all groups six months post-vaccination and show a marked reduction in the serological binding and neutralizing response targeting Omicron compared to other viral variants. We also highlight the increase in cross-protective neutralizing antibody responses against Omicron induced by a third dose (booster) of vaccine. These data illustrate how key virological factors such as immune escape mutation combined with host factors such as age and sex of the vaccinated individuals influence the strength and duration of cross-protective serological immunity for COVID-19.
Licencia
cc_by_nc
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Cohort_studies / Experimental_studies / Observational_studies / Prognostic_studies / Rct Idioma: En Año: 2022 Tipo del documento: Preprint
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Cohort_studies / Experimental_studies / Observational_studies / Prognostic_studies / Rct Idioma: En Año: 2022 Tipo del documento: Preprint